Dac orks: PAL.
`,
`Document Desariptian: Power of Attorney
`
`Urrcler tha Pays
`
`work Reduction Actof 1995, no persons ane reginath regognd weRo
`
`PTAIARE
`Tos
`S28
`Appenvedd fur use Meaugh GYEVEOTE CMB
`
`S. Patentand‘FradomarkoF
`3.
`TMERTOF©SOMMERoe
`svete TMB pontenumber
`
`
`
`rc herebyrevokeal SSae af atorney ¢givenin the apalication jdentiled in gither
`
`
`ar oe
`the boxes38 below,
`
`
`
`3 33
`
`5 } } } |
` ; ; ;i 3 3 :j444444444$;44444
`Application Nunther
`Filing Date
`
`
`
`
`
`1 } } | | i 1 | 1 } | } 1 5 4 |Lenereseretarncrrereed
`
`
`(Nek: The boxes abaya may betellblank if informationisg provided onfora,BFOIAIAS2A}
`| hereby appointthe Patent Practiionerts) associated with the following Custorner Number gs my/our attorney{s) or aganiis}, and
`te trangect all business inthe United States Patent and Trademark Office connectedsherewith|iorthe apolication refererioad in
`the allachedfransrniftal letler form FTOMAIA/S24)or identified abaya: [~
`"
`7
`
`OR
`losccosstecceecbensosudhcitusseeeseeeegeeesseeraartunuune isan
`] | hereby ancoint Practificoner(s} named in ihe allachad fist {form PTOIAIA/S20) as myour alicrrey(s) or agant{s), and to transact
`
`ali business in the United States Patent and Trademark Office cnnnectad therewith for thegatent application referenced in the
`
`attached transmittal lelier (loom PTO/AIAGZ4)or
`Kdeallied above. (Note: Cornplete forra PTOMMIAB2C.)
`
`Please recognize.archange the correspondence asidreress for the application ideniified in the attached tranamittal
`ieter or the boxes above to:
`The address associated with the above-mentioned Customer Number
`ml
`oR
`[ The address acencatad with Customer Number
`QR
`
`Firm ar
`individual Name |
`
`|
`
`|
`
`
`
`i Acidrass
`
`Caiky
`
`
`
`
`
`Cauntty
`| Email
`i Telephone
`ny arthe Applicant {¥ the Apoficant is a jurists entity, lisi the Applicant name in the Gog):
`Exela Pharma ScieieancesLLC
`
`[ fvenitar or Joint invert
`F title Bot required below)
`i|Lagat Repreeentalive of a Deceased or Lagally incapacitated iiventer(tie not required below)
`
`Assignee of Persan to Whom the Inventor is Under an Obligation to Assign (pravide signar’s title ff applicant is a ae entity}
`
`|p son Whe Othensise Shows Sufficient Prapristary Interest (s.q., a pation under37 CFR 1.4O(bN2} was granted int
`aplication or is conourrerdy being filed with this dpcument) (oruvide signer’s tlle 1applicant is afutistic enity}
`SIGNATURE af Applicant fer Patent
`
`The anderssigned (whosePR
`Serrererrrrte
`
`autharized to act an behalf of the applicant ie
`., where the apaliant is x iutistlc erdityh,
` Date elena ‘
`Sere
`Sigiae:
`Name
`
`Tiths
`NOTE: Slanaiure - This fore must be signed|iy the apeficant in acconmance with OY CFR £93. See a7 CFR 1.4 for signature requirarnants
`
`and certifications. i more than one appiioant, aae truliple forms.
`[erofonesee SIMSareBUbIItiNd
`
` See we
`
`
`
`Necker i@ estinaledte gale 2 minutes te Gomplats,
`salay SBP
`Jncturtinggatherieg prepay
`cepted ayy
`@PTO
`ar
`
`
`
`
`qQ upon the inividual case. Any commants on the amount
`
`ef ine you require to canny
`fam Hon suggestions forFadeANG, thiei san, ehouid besont % the ¢
`viet Infeaymation Ch
`ent and Trademark Glico, U8,
`
`
`
`DRMS TO THIS ADORESS. SEND TO: Gommicsioner
`
`Ceaparimert of Commerce, PG, Bax 145m, Alexandria, Vid STS480, Exo RT SEND PEES OR OOMPLE}
`tor Patents, PQ. Bax 2480, Aloxenarde, VA 22343-74988,
`# poe Hoed assictanosin completing tis fan, call 7-800-P7O0108 aad sefeel agdion 2.
`
`
`
`{
`
`
`
`
`
`
`
`
`
`Nexus Ex. 1002
`Page 1 of 225
`
`Nexus Ex. 1002
`Page 1 of 225
`
`

`

`
`“4 at dat
`UNITED STATES
`Le OL 00) pcrent ano TRADEMARK OFFICE
`
`Page 1 of 2
`
`soeccemrate yotai1499
`Alexandria, VA223153nears
`
`ELECTRONIC PAYMENT RECEIPT
`
`APPLICATION #
`TSG?287
`
`RECEIPT DATE / TIME
`Ve/TS/V0N2 VS33.16 PM ET
`
`ATTORNEY DOCKET#
`OGGSSG/HS9G7S
`
`Title of Invention
`
`STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USE
`
`Application Information
`
`APPLICATION TYPE=Utility - Nonprovisional Application PATENT#
`
`
`under 25 USC Tiifa
`
`CONFIRMATION #
`
`$793
`
`FILED BY
`
`aque! West
`
`PATENT CENTER#
`
`67312426
`
`AUTHORIZED BY Bryan Skelton
`
`CUSTOMER#
`
`826
`
`FILING DATE
`
`CORRESPONDENCE
`ADDRESS
`
`-
`
`PaymentInformation
`
`FIRST NAMED John Maloney
`INVENTOR
`
`PAYMENT METHOD
`DA / 180805
`PRE-AUTHORIZED ACCOUNT
`
`PAYMENT TRANSACTION ID
`ESOS2RFFIS5331 48
`PRE-AUTHORIZED CATEGORY
`
`PAYMENT AUTHORIZED BY
`Raguel Weal
`
`160805
`
`3? CFR 1.78 (National application Bling, search, and examination fees); 3¥
`CFR 1.417 (Patent application and reexamination processing fees}; Jf CFR 1.19
`{(Bocumant supply fees}; JF CPR 1.20 (Post issuance fees); 37 CFR 1.21
`(Miscellaneous fees and charges}
`
`FEE CODE
`
`DESCRIPTION
`
`ITEM PRICE($)
`
`QUANTITY
`
`ITEM TOTAL($)
`
`WOT
`
`wi
`
`1202
`
`VERO
`
`BASIC FRING FRE - UTIUITY (PAPER
`FILING ALSO REQUIRES NON-
`LEG PRONE FIUNG FEE UNDER
`
`armaeid
`
`PATENT APPL. EXAMINATION FEE
`
`EACH CLAIM IN EXCESSOF 30
`
`PROCESSING FEE, EACEPT IN
`PROVISIONAL APPLICATIONS
`
`320.00
`
`SHOW)
`
`7OO.00
`
`140.00
`
`1
`
`:
`
`oe
`
`7
`
`320.00
`
`800.00
`
`1003.00
`
`140,00
`
`Nexus Ex. 1002
`Page 2 of 225
`
`Nexus Ex. 1002
`Page 2 of 225
`
`

`

`Tai?
`
`Hi
`
`REQUEST POR PRIORITIZED
`EAAMINATION
`
`UTILITY PATENT APPL. SEARCH
`
`Ree
`
`4200 00
`
`706.00
`
`7
`
`1
`
`Page 2 of 2
`
`4200.00
`
`700.00
`
`TOTAL
`AMOUNT:
`
`$7,180.00
`
`otad date oy the USPTO of ihe Inchcated dacurments, charach:
`
`This Acknowledgemgnt Receipt eviiance
`
`
`lar lo a Post Care, as
`oy Ing apohcant, and including page caunts, where appiicabie. i serves as evidence of recgipt s
`desorbed in MPEP 803.
`
`
`
`New Aplications Under 35 S.C. iit
`
`fia new acpolication is osing filed and the agnlicabon includes the necessary components for fing da
`and MPEP 504), a Filing Receipt (@? CFR 1.94) wil be issued in due course5 and the dale shawn on
`Receiot wil establish the filing date of the appiicalian
`
`National Stage of an btiernational Application uncer 35 U.S.C, 3ft
`ncadior: iS Gormollant wilh the conditions of GG WS.c.
`Hfadimely submission io enter ihe national stage of an ink
`
`
`ing acceptance of the agmicalion as a nahonal stage
`371 and other acplicable requirements a Form POT/DO/E
`i
`submission under 35 US.0. S71 wil be issued in addition to the Fling Receipl, in due course.
`
`New International Application Filed wilh the USPTO as a Recelving Office
` 8 being fed and iheint
`H cc ri@winternations
`K
`qadonal aomication includes the necessary comoanents for ar
`vs
`tian of the international Anohcation Number and of theinfernational fing date (see PCT Anicie 17 and MPEP 1819), a Notiic
`
`
`nal Filing Dale (Form PCT/RO/1 08) will be issued In due course, subject to prescriotions concerning nationalJ security,
`
`
`inferrialio
`
`and the date shawn on this Acknowlecgemant Receipt will establish the intematio
`nal filing clate af the applicaiion.
`
`Nexus Ex. 1002
`Page 3 of 225
`
`Nexus Ex. 1002
`Page 3 of 225
`
`

`

`
`PTOUMASTT (08-12
`
`Agoravedd for us
`s through PHQUORO, OMS US8t-00S
`LES. Patent atedTrademark CA
`U5. DEPARTMENT OF COMMERCE
`
`
`SeennenienenARISESEEEEECLELAND
`fephays @ valid GME Cantal neineay,
`lan of ingceen
`\
`SN
`SOOESEMINAR
`neler tie Papapyork Asdatitt: Act oF G99, no Deysane ars raquiedd io ragpond to a cof
`
`
`
`
`invention [METHODS OF USE
` Sone nono DOSERASO NOC OOSTOOOS CoN SOSAEERE
`
`
`
`
`:
`y
`As the belowfamed inventor, | Nereby deciare that
`
`DECLARATION (37 GFR 1.93) FOR UTILITY OR DESIGN APPLICATION USING AN
`APPLICATION DATA SHEET (37 CFR 1.76)
` Oeaennnunaaannnny
`SanaaRAENSvnsnannanaaanAns
` nrcan au Aaa
`SASLSAAR
`AAAI 4
`
`
`Title of
`| STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS POR AVECTION AND
`
`
`
`
`
`
`
`This declaration
`es
`Sees
`is directedto:
`
`vgacgtien
`,
`The attached application, ar
`SROES SEDEEEION.
`GF
`ce United Stetes aaplication ar PCT Interaatinnal applioation ouraber
`January 15, 2018
`fled on
`
`16/248,460
`
`
`
`
`
`The ahoveidentified spolication was mada of authorized to ba made by me.
`
`
`
`a
`+
`a
`y
`| believe that | an the ariginal inventar or an original joint inventor of a dainted invention in the applinalion.
`
`lt heraby acknowledge that any willldfalse sialement made in this destaration is punishable under 18 U.S.C. 1004
`i by fine or ivipsonment of not more than |five {5} years, or bath.
`
`
`
`
`
`
`f Petiionasanplicantis cautioned to avoid submiling personal informationin ciocurnants Med in a patent application that may
`t contribute to identity theft. Personal information such as social senurily numbers, bank account rursbters, ar credit card rurnbers
`{ (ather thar: a check or credit card authorization form PTO-2098 submitted for payment purposes} is never required by the LISPTO
`hin suport a pefition or an apotication.
`Hf this lypeof personal Information is Inchuled in documents submified tp the USPTO,
`
`
`| patitioners/applicanix should censider redacting such personal information fromthe documents before submitting them fs the
`
`
`HUSPTOL Pelitioner/apolicant is advised thal the record of a patent pepeign is avellabte to ihe public afterpeublication of the
`
`
`| application (unless 3 non-publication requeal in compliance with 3? CFR (.219fa) is made in the application) or issuance of a
`
`
`patent. Furthermore, the record fromant abanejoned sppiicstion may also be available ig the public H the application is
`referenced in a published apnieation or
`an Issued patent (see 37 GFR 144), Ohacks and oredit card authorization ve
`
`PTO-2038 submithed for payment purnose8 are mot retained in the apolination fle and therefore are nat publicly availabl
`so
`
`
`WARNING:
`
`
`
`
`
`LEGAL NAME OF INVENTOR
`
`
`
`
`
`| Note: An application data shast (PTOASB/14 or equivalent], including naming theentire inventive emily, must accerapany this form or must have
`
`i bean previnisly fies. Use an additional PTOVALAAH form for each ardilional inventar,
`crncenne AEDEENESTEEEEEEEELESSEEEEEIENANASSAMESSTEERS
`
`Sollseticns oF informationie requited by 88 WAG iand AF CFR Tf
`The ieddesrerstisss iScere fo“obtainonretain aGenekteeihe gubtis whinkis to file fand
`
`
`
`by the USP YO tn process} an application, Confiden
`2
`Hs
`ase tmnuie te
`
`
`Jing gathering, preparing, snd submis
`s av
`eames:
`Seggestions‘or facwotag
`thesnurden, shouxe be sentii
`Pee ERITH OF fete Gas Fequize to 6:
`SHIT
`
`
`
`
`
`
`Patent and TraderOtiee, U.S. Oapartment of Comnene, FoQ. Sox 3IH, Alexandria, YAZES1S-1440, DoNOT SEND F:ES ¢oR COMPLETED aIS T
`ifs
`THIS ADDRESS. SEND TS: Commissionerfor Pafonis, P.O. Ban 1480, Alexandria, VA 22319-4858,
`
`fanoe a connstedieg trefoun, cal EOPPOSTRS sud sdfaal onlion 2
`
`Nexus Ex. 1002
`Page 4 of 225
`
`Nexus Ex. 1002
`Page 4 of 225
`
`

`

`PTO/AIA/01 (06-12)
`Approved for use through 11/30/2020. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collectionof informationunless it displays a valid OMB control number.
`
`DECLARATION(37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
`APPLICATION DATA SHEET(37 CFR 1.76)
`
`|SABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND
`Titleop
`invention|METHODS OF USE
`
`Asthe below namedinventor, | hereby declare that:
`
`This declaration
`
`is directed to:
`
`‘nati
`
`The attached application, or
`[|
`im] United States application or PCT international application number 16/248,460
`filed on YaNuary 15, 2019
`
`The above-identified application was made or authorized to be made by me.
`
`| believe that | am the original inventor or an original joint inventor of a claimed invention in the application.
`
`| hereby acknowledge that anywillful false statement made in this declaration is punishable under 18 U.S.C. 1001
`by fine or Imprisonment of not more thanfive (5) years, or both,
`
`WARNING:
`
`Petitioner/applicant is cautioned to avoid submitting personal information in documentsfiled in a patent application that may
`contribute to identity theft. Personal information such as social security numbers, bank account numbers,or credit card numbers
`(other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO
`to support a petition or an application.
`If this type of personal information is included in documents submitted to the USPTO,
`petitioners/applicants should consider redacting such personal information from the documents before submitting them to the
`USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the
`application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a
`patent. Furthermore, the record from an abandoned application may also be available to the public if the application is
`referenced in a published application or an issued patent (see 37 CFR 1.14), Checks and credit card authorization forms
`PTO-2038 submitted for payment purposesare not retained in the application file and therefore are not publicly available.
`
`LEGAL NAME OF INVENTOR
`
` This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public whichisto file (and
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`a
`
`Inventor: ArunaKog nti
`Signature:
`:
`
`2
`Leoe
`
`Date (Optional) :
`
`Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompanythis form or must have
`been previouslyfiled. Use an additional PTO/AIA/O1 form for each additional inventor.
`
`by the USPTOto pracess) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to
`complete, including gathering, preparing, and submitting the completed application form to the USPTO. Timewill vary depending upontheindividual case. Any
`comments on the amountoftime you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S.
`Patent and Trademark Office, U.S. Department of Commerce, P.O, Box 1450, Alexandrla, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO
`THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`Ifyou need assistance in completingthe form,call 1-800-PTO-9199 andselect option 2.
`
`Nexus Ex. 1002
`Page 5 of 225
`
`Nexus Ex. 1002
`Page 5 of 225
`
`

`

`Invention METHODS OF USE
`SONRERMn Soe
`nen ‘
`
`As the below named inventor, | heraby declare thet:
`
`a
`This declaration [|
`ae
`.
`“he allached sopication, or
`.
`.
`is directed fc:
`SRQEROG
`BARE
` ins apolication or PCT international apolication surniber
`f
`fled on, danuary 15, 2019
`
`6/248 460
`
`
`
`
`
`
`
`| The sbove-idaentified application was made ar authorized to be mde Dy me.
`
`
`
`
`een {O81}
`
`Aggurowed dup use dipough THs
`y
`GSS} O32
`rat
`
`US. Fatentand Traci OF
`iG. DEPSRI MENT oF SONWMERTE
`
`
`
`
`
`
`
` cle
`arenernAEEENLRLAAIEEREALAIN
`1 of information unfiiss § displays a valkt OMB contraninatar.
`Ureter tha Papenvork Reduction Act of 1995, na persche ars required to respond to. a So!
`DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
`APPLICATION DATA SHEET (37 CFR 1.78)
`
`SOESONEAAAAAANSID
`HHOELAS
`SS
`SET SESEERscoscddocococoeeeSSESLRSERAAAAOOOONENEELENRRAEN
`
`
`I STABLE, HIGHLY PUREL-OYSTEINE COMPOSITIONS FOR INJECT!ON AND
`Title of
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`WARNING:
`
`
`i Petiionarapplicant is cautionad to avon! subsulling parsenal informalioh in documents fied in a patent application that may
`‘ contribuie to identiineft. Personal information suchas socksilseounty numbers, hank aceaual nunibers, or credit card numbers |
`
`iian forra PTO.
`2038 submitted for payrnent purpuses) is never faquired by the USPTO|
`{other thar & checkor credit card auihorizal
`
`PSO
`in support a petition or an application.
`ffthis type of personal Informationis iolded in documentsis submitted fo the USPTO,
`i
`patiionersdanolicants atiould consider redacting auch persson
`information frornihe docurnenis before submitting thento the
`
`
`i
`ay
`
`USPTO. Pelificnerapplicant is advised that the renord of a paterootaig available to the public fier publication of the
`
`
`| application (unises a narqublication request in nomnlianorv
`tee434Sta}|is made in the application) or issuance of 8
`
`lable fo the public # the spoplication is
`foatent, Furtherrnore, ihe record from an abandoned applinatia
`
`f refereficad ina pubMished application of an kssusd patent fsee“37 CPR t.4) Checks and creditcami aulhorizatinn forms
`
`
`not retalned in the application file and herefore are not publicly available.
`PPTOMGUSS submitted for payment purposes are
`
`
`SERIE coco
`Rononaanetn
`
`
`
`Phanesh Koneru
`
`Date (Optional:
` Stonalure: SERVAAAAAAAAAISINNEBERAAPPTRELLIE
`
`
`
`
`
`
`
`pyparry Gus fren or mnast have
`Note: An auplination dala shect (PTO/SBI4 or equivalent), Including narding the antics Inventive entity, must e
`bean previausly fled. Use an gditional PTOIAMAK i fares fer each
`additional Inventor.
`
`
`
`
`L cosianvnanennnnniinnsanAtSAAARARARARAAAAAANIAIDOENOMENONprocera
`
`
`This callaction of Information is
`aquired by BELLS. 106 and 7 GPR 1.83. [he inftemation i reqgibred to
`
`
`
`bythe USPTO to prossed ath application. tanks anilatity is governed by SO W560. 1ae and3ay CFRUT
`
`
`cormaieas, inching gsthering, preparing, and siubstitt!
`
`
`
`
`
`gammenis on the amount of time you squire bo cana
`tis
`yb ns thus Chey devise
`
`'qis Stexarndda, Ve 2254 B4A50, |
`areSe
`BUR COMPLET
`Patent ad Trademark Offies, GS, Repariment of Cammveres, PG.
`
`
`
`THIS ADDRESS, SSNDFO: Commissioner for Patents, P.O. Bex 1450, Alexancirin, VA 22353-3400,
`ifyou needaasisisoces fy commatingihe form, cal P3008PO-0758 and setect aAnon2.
`
`} believe that | ana the original inventor of an original joint inventor of a claimed inventianin the application.
`
`[i hereby acknowledge thal any willful false statement made in this declarationis purrishaala under 1BULS.0. 100%
`| by fine or imerisenment of not more then five {5} years, or both.
`
`LEGAL NAME GF INVENTOR
`
`inventor:
`
`csen, Any
`ORGLS
`03 FORMS TO
`
`Nexus Ex. 1002
`Page 6 of 225
`
`Nexus Ex. 1002
`Page 6 of 225
`
`

`

`
`od atdat
`UNITED STATES
`| URS] OPE OR ocrent ano TRADEMARK OFFICE
`
`Page 1 of 4
`
`souancria, ye Agaeo* 1488
`Heeeen eertienidgay
`
`ELECTRONIC ACKNOWLEDGEMENT RECEIPT
`
`APPLICATION #
`18/067,287
`
`RECEIPT DATE / TIME
`12/16/2022 03:33:16 PM ET
`
`ATTORNEY DOCKET#
`066859/589619
`
`Title of Invention
`
`STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USE
`
`Application Information
`
`APPLICATION TYPE—Utility - Nonprovisional Application PATENT#
`
`
`under 35 USC 111(a)
`
`CONFIRMATION #
`
`9793
`
`FILED BY Raquel West
`
`PATENT CENTER#
`
`61312420
`
`FILING DATE
`
`CUSTOMER #
`
`826
`
`CORRESPONDENCE
`ADDRESS
`
`-
`
`Documents
`
`FIRST NAMED John Maloney
`INVENTOR
`
`AUTHORIZED BY Bryan Skelton
`
`TOTAL DOCUMENTS: 11
`
`DOCUMENT
`
`PAGES
`
`DESCRIPTION
`
`SIZE (KB)
`
`589079ADS. ocd
`
`589819TRACKTodi
`
`589819PAM of
`
`588STSPAM-A.PE oct
`
`cit}
`
`589619_PAM-SPEC pdf
`
`{2-23
`
`589619PAM-REM_oelf
`
`(3-3)
`
`S886 19DWOS. paf
`
`9
`
`2
`
`3
`
`7
`
`7}
`
`]
`
`5
`
`Apoication Data Sheet
`
`ei74 KB
`
`Track One Request
`
`-
`
`Preliminary Amendment
`
`opeciication
`
`Applicant Arqumenis/Remarks
`Made in an Amendment
`
`FO KB
`
`168 KB
`
`193 KB
`
`703 KB
`
`703 KB
`
`Drawings-only Dlack and white
`
`'25 KB
`
`Nexus Ex. 1002
`Page 7 of 225
`
`Nexus Ex. 1002
`Page 7 of 225
`
`

`

`Page 2 of 4
`
`ine drawings
`
`Oath or Declaration Hed
`
`354 KB
`
`Change of Address
`
`~
`
`specication
`
`Claims
`
`Abstract
`
`P?6 KB
`
`621 KE
`
`605 KB
`
`74 KB
`
`55 KB
`
`3
`
`7]
`
`o4
`
`ay
`
`8
`
`1
`
`(1-B?}
`
`(88-3:3}
`
`(94-94)
`
`§89819_DECpdf
`
`S89619_POA nd
`
`884619TRACK tcon.pdl
`
`589619 TRACK tcan-
`SPEC pdf
`
`589619TRACK tcon-
`CLM. pat
`
`589619TRACK ican-
`ABSTpdf
`
`Digest
`
`DOCUMENT
`
`MESSAGE ONSEST(SNA-312)
`
`S88619ADS. od
`
`4003 DSCGR4 1 G2ACEPE72827 TSFOCSO4AG3S31 AGSEBFOTTESD?
`
`O54 2 0F 5349SADSAEDAG27FDGB4OF 1 SBE I BEAST BFCB?STORSS
`
`21 ASSECFFERDAAACLABCACORAS ARF
`
`889819TAACK pdi
`
`S6F TE SGS29ER ECE BEDSSE TOACDDECGSSGF 17 RO3891 73aCes
`
`FBOCSOLBSFS 7 BOQSCALAFCAAFOSAC SIS BOTGFOAF BQ04 DIAS
`
`48513057 7FG5 7 PAPFOSOCFRCSGT7 ADC
`
`589819PAM. pdt
`
`eC SD 1GCE DAFFAE B4S383D7 CAEF/CGe2707 | COESBSES?S
`
`SBSATS2AGESOR7 7 DASAE 1 SBSFSOLDCS42 1 420 DCS44 ABROAD
`
`A5SSOCCASSSFRAOCASESCFS5SO1 GFE SAT?
`
`S89519PAM-A PE nai
`
`DFE46003705 1 SFSDBS95 7 ROCSGARASE 302247 7OSF DOOBSFAG
`
`CASSS025BA4ARDYSEG9TO6GA75ATSBCORAGSS7SEBE76BFS1
`
`DPF FOD480565 74BO43F43D8CS8Bol BE
`
`589619PAM-SPEC pal
`FOPST2TBFEG? I GESEAESSBSCF4FSCTSATSS0|QDSDSRS72CK2
`
`Nexus Ex. 1002
`Page 8 of 225
`
`Nexus Ex. 1002
`Page 8 of 225
`
`

`

`2384575462 34F COQ82 BSFESCA? TESGDSSBDAT EA BSSFCBZE56
`
`PLISB OSS29 ALAS DAT DABTAAATEA
`
`Page 3 of 4
`
`S89619PAM-REMpci
`
`SDO62RCSFFSOCERCDABOBABDARD 1 CDSS 7S2RaS8SAL251 STESS
`SIMI BS7EGES 1 S848COB PSE SOSOF7A707 DeSAQBOF? DSSABCOG
`
`baa TZAPSPrE4SRO430k 1 PSR BReSoReS
`
`589819DWOS.paf
`
`S806 19DEC ndt
`
`S89819POA pdt
`
`SDODECCOS9S8 C9 ESESASOS3DACBS4N4506E701 SE2eDCBEOFG
`91 BAAI FF RSSAS 0R0D6F 840490061096S ASSBESSDOSETE4F1
`
`OFFPSA] A7OCBERSFE ST DESI DSFADA
`
`CB8sAe4enesesebeGe!) 1 Bi SDAPEDE |COzo25C64COCARSO2ZTD
`BOCABRSBO11 4D7462R1 S20D3GR02DCAAT TGAAOESCTFRSSO7GC?
`
`FOGATO41 7F26C7AAGAFGCEEATOE GARDE
`
`{40A4853D93 1 DOAT?T? 1 ASSCAZELSACSE2) AAGFSBCFS2007438
`97 DS 7404ASSES CCEOO4ARGCS Tt ASD S24 00 O DSF 56/7Coe bSb4Ady
`
`CDSSEASTDESCEDPAdS4 DASEFAOSOP
`
`S596 19TRACK toon. pet
`
`STB TSCCS86RGA9 1 SB2G9S9RECA4SSPACK SS54E1 TSEG7EAFDA
`DE FSS COCSSSABODSDGAESECOC 1 SFOACRBRGI FER 1 27 D54933F
`
`SBTSOSESEAC TE FGOSS4D FE2SAQS B443
`
`S89619TRACK ison SPEC. od?
`
`er?7AGADSEABIRDE ASS SS46C43 1 C7Ol 285e7 FEVSFECIC 1 ASG
`S47P68E587FC1 SS4CD0DD 17978CC5 7ASCEFT 145A97FABS
`
`S507a1 eOS326084 1 CAEGSBAEGASE
`
`S89619TRACK tcon-CLM_ oct
`
`4ABSOEBBCSOCOU4ADZIBRE ASG 1 EGGAE 7408939F F235 /625R02 14AB
`SDCS4S S834 F 260C95CR7AEP BOABSSFCCDESSSSBSSEFIS19S
`
`SEC ASQDOSFE43 CFAAEF7240 29D RRSP?
`
`589619TRACK ison-ABST pdf
`
`7 FOSYSFASSB2O8D91 FERFCADSSS2RA5E5FF34AR0ARDDCr24 |
`POSCCOSS9AF5 1 CR4DESC4SQSBEAS /OCBSDESS TAT ESBSEOD
`
`AAG TF] IGBRSGSSIDAPSESTEIS?TSEOTS
`
`i Receipt evidences receint on the noted date by the USPTO of ine incicated documents, charectarizad
`This Acknowlsdgerns
`
`
`
`ding page counts, where aonicable. iserves as eviderice of recejpl similar to a Posi Card, as
`ny the applicant
`described in MPEP 50:3.
`
`New Applications Under 35 WLS.itt
`fa naw applicalign is being fled and ine application includes ine necassary components for fing date (see 37 CFR LSS(b idk
`
`Nexus Ex. 1002
`Page 9 of 225
`
`Nexus Ex. 1002
`Page 9 of 225
`
`

`

`Page 4 of 4
`
`and MPEP §96), a Filing Rese!
`Recent wil astablish the fling
`
`@ annlicadhan
`
`ROS) will be issued in due course and the daie shawn on this Ackraawiedgement
`
`National Stage of an international Application under $8 U.S.C. 374
`
`Hea fimely submission io enter ihe national stage of anivanesal aopiication is compllant wilh the conciifiaris of 95 LLS.c.
`due course.
`indceding acceptance af the agmicalon as a nabonal stage
`Fling Receipt in
`New International Application Filed with the USPTO as a Recelving Office
`
`aliorial aoplication includes the necessary comoonents for an
`wig fect anc iheip
`
`interrialtional Eling£rate |(Form POT/RO‘ 05) will be issued In due course, subject to prescriotions concerning national securiy,
`CT Article tT] and MRFEP 1819), a Notification of ihe Inernational Apolicatian Nurnber and of the
`
`
`and the date shownon this Acknowledgement Receipt will establish the international fling date of the application.
`
`Nexus Ex. 1002
`Page 10 of 225
`
`Nexus Ex. 1002
`Page 10 of 225
`
`

`

`Doc Code: TRACK1.REQ
`DocumentDescription: TrackOne Request
`
`PTO/AIA/424 (04-14)
`
`CERTIFICATION AND REQUESTFOR PRIORITIZED EXAMINATION
`UNDER37 CFR 1.102(e) (Page1 of 1)
`
`First Named
`
`Nonprovisional Application Number(if
`von
`John Maloney
`STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USE
`
`APPLICANT HEREBYCERTIFIES THE FOLLOWING AND REQUESTS PRIORITIZED EXAMINATION FOR
`THE ABOVE-IDENTIFIED APPLICATION.
`
`1. The processing fee set forth in 37 CFR 1.17{i)(1) and the prioritized examination fee set forth in
`37 CFR 1.17(c) have beenfiled with the request. The publication fee requirement is met
`becausethat fee, set forth in 37 CFR 1.18(d), is currently $0. The basic filing fee, search fee,
`and examination fee are filed with the request or have been already been paid.
`| understand
`that any required excess claims fees or application size fee must be paid for the application.
`
`| understand that the application may not contain, or be amended to contain, more than four
`independent claims, more than thirty total claims, or any multiple dependent claims, and that
`any request for an extension of time will cause an outstanding Track | request to be dismissed.
`
`3. The applicable box is checked below:
`
`forms are submitted.
`
`A request for continued examination has been filed with, or prior to, this form.
`If the application is a utility application, this certification and request is being filed via EFS-Web.
`iii. The application is an original nonprovisionalutility application filed under 35 U.S.C. 111(a), or is
`a national stage entry under 35 U.S.C. 371.
`iv. This certification and request is being filed prior to the mailing of a first Office action responsive
`to the request for continued examination.
`No prior request for continued examination has been granted prioritized examination status
`under 37 CFR 1.102(e)(2).
`
`i.
`
`(a) The application is an original nonprovisional utility application filed under 35 U.S.C. 111(a).
`This certification and request is being filed with the utility application via EFS-Web.
`---OR---
`{b) The application is an original nonprovisional plant application filed under 35 U.S.C. 111{a).
`This certification and request is being filed with the plant application in paper.
`
`An executed inventor's oath or declaration under 37 CFR 1.63 or 37 CFR 1.64 for each
`inventor, or the application data sheet meeting the conditions specified in 37 CFR 1.53(f)(3)(i) is
`filed with the application.
`
`pate December 16, 2022
`sinane/Bryan L. Skelton/
`
`Nameegbryan L. Skelton Practitioner 20893
`
`
`
`(Print/Typed)
`Registration Number
`
`This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d} for signature requirements and certifications.
`Note:
`Submit multiple forms if more than one signature is required.*
`*Total of 1
`
`Nexus Ex. 1002
`Page 11 of 225
`
`Nexus Ex. 1002
`Page 11 of 225
`
`

`

`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your
`submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of
`the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2)
`furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the
`U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or
`patent.
`If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to
`process and/or examine your submission, which may result in termination of proceedings or abandonmentof the
`application or expiration of the patent.
`
`The information provided by youin this form will be subject to the following routine uses:
`
`1. The information on this form will be treated confidentially to the extent allowed under the Freedom of
`Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may
`be disclosed to the Department of Justice to determine whether disclosure of these records is required by the
`Freedom of Information Act.
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence
`to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of
`settlement negotiations.
`A record in this system of records may be disclosed, as a routine use, to a Memberof Congress submitting a
`requestinvolving an individual, to whom the record pertains, whenthe individual has requested assistance from
`the Memberwith respect to the subject matter of the record.
`A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having
`need for the information in order to perform a contract. Recipients of information shall be required to comply
`with the requirements of the Privacy Act of 1974, as amended, pursuantto 5 U.S.C. 552a(m).
`A record related to an International Application filed under the Patent Cooperation Treaty in this system of
`records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property
`Organization, pursuant to the Patent Cooperation Treaty.
`A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes
`of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C.
`218(c)).
`A record from this system of records may be disclosed, as a routine use, to the Administrator, General
`Services, or his/her designee, during an inspection of records conducted by GSA aspart of that agency's
`responsibility to recommend improvements in records managementpractices and programs, underauthority of
`44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing
`inspection of records for this purpose, and any other relevant(/.e., GSA or Commerce)directive. Such
`disclosure shall not be used to make determinations aboutindividuals.
`A record from this system of records may be disclosed, as a routine use, to the public after either publication of
`the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a
`record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record
`wasfiled in an application which became abandonedorin which the proceedings were terminated and which
`application is referenced by either a published application, an application open to public inspection or an issued
`patent.
`A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law
`enforcement agency,if the USPTO becomes awareofa violation or potential violation of law or regulation.
`
`Nexus Ex. 1002
`Page 12 of 225
`
`Nexus Ex. 1002
`Page 12 of 225
`
`

`

`1/5
`
`Dissolved Oxygen Levels per Tray
`
`DO(ppm)
`
`14.0
`
`12.0
`
`10.0
`
`8.0
`
`6.0
`
`4.0
`
`2.0
`
`0.0
`
`RNOSS
`S.
`SH
`&
`ES
`
`ee SYSRN
`
`
`
`
`
`
`
`
`atesTray 1
`sedis Tray 2
`segeenTray 3
`assives:Tray 4
`
`amgiosTray 1
`
`seins: Tray 1
`
`sonTray 1
`wana[1gy 21
`
`Tray 2
`sentiesTray 2
`
`sottoTray 2
`
`Post HSR -Capping -
`Post Filling - During
`Final Dissolved
`Filled Vials
`Loading of Lyo
`Oxygen Compounding
`
`
`Post Filling -Pre HSR_
`
`FIG. I
`
`Nexus Ex. 1002
`Page 13 of 225
`
`Nexus Ex. 1002
`Page 13 of 225
`
`

`

`2/5
`
`14.0
`
`12.0 10.0
`
`““Do(ppm)
`
`|
`;
`
`B.0
`
`6.0 ;
`:
`4.0
`
`\
`\
`&ooo
`
`XS Sgn.BOM”
`
`X
`a\
`RgSS
`
` 1
`
`2
`
`3
`
`4
`
`17
`
`18
`
`#19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`%37
`
`#38
`
`39
`
`40
`
`«“&s««PostFilling DO (ppm)
`Tray Number
`segs Com pounding DO (ppm)
`asaiess Post HSR DO (pom)
`«Lyo Loading DO (ppm)
`
`
`Nexus Ex. 1002
`Page 14 of 225
`
`Nexus Ex. 1002
`Page 14 of 225
`
`

`

`3/5
`
`L-Cysteine Setup for Protocol and DO Testing Points
`
`Argan Overlay
`
`
`
`DO Testing
`
`DO Testing
`
`Pulses
`Wail
`
`Gas Stoppering with 3
`
`Further D.O. Testing after capping unless Senet
`otherwise stated,
`
`FIG. 3
`
`Nexus Ex. 1002
`Page 15 of 225
`
`Nexus Ex. 1002
`Page 15 of 225
`
`

`

`4/5
`
`fhannyYarPiped
`
`ces
`
`2
`esWw
`
`SS
`Ree
`
`a
`
`FIG. 4
`
`Nexus Ex. 1002
`Page 16 of 225
`
`Nexus Ex. 1002
`Page 16 of 225
`
`
`

`

`5/5
`
`%y:%:Ya%,UlliVill,
`
`1%|::Ns
`ey:::
`My“
`
`SANTi
`
`i5eo
`
`:Ye
`
`Sa O
`ASSOLR YREA
`
`sagQen He
`
`FIG. 5
`
`Nexus Ex. 1002
`Page 17 of 225
`
`Nexus Ex. 1002
`Page 17 of 225
`
`
`
`
`
`

`

`PATENT
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Appl. No.:
`Applicant(s):
`Filing Date:
`Art Unit:
`Examiner:
`Title:
`
`Confirmation No.: Unassigned
`Unassigned
`EXELA PHARMASCIENCES, LLC
`Herewith
`Unassigned
`Unassigned
`STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR
`INJECTION AND METHODS OF USE
`
`Docket No.:
`
`066859/589619
`
`CustomerNo.:
`
`826
`
`Commissionerfor Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`PRELIMINARY AMENDMENT
`
`Sir:
`
`Please enter this Preliminary Amendment before calculating the claim fee and amend the
`
`above-identified application as follows:
`
`Amendments to the Specification begin on page 2 of this paper.
`
`Remarksbegin on page 3 ofthis paper.
`
`LEGAL02/42433776v1
`
`Nexus Ex. 1002
`Page 18 of 225
`
`Nexus Ex. 1002
`Page 18 of 225
`
`

`

`Application No.: Unassigned
`Preliminary Amdt. dated December 16, 2022
`Page 2
`
`Amendments to the Specification:
`
`Please amendthefirst paragraph ofthe specification as follows:
`
`CROSS-REFERENCE TO RELATED APPLICATIONS
`
`This application is a continuation of U.S. application no. 17/950,964 filed September 22
`
`2022, which